Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER) Forms New Partnership with KOA(R) and Yogi Bear’s Jellystone Park(TM) Camp-Resorts

The Alkaline Water Company (CSE: WTER) (NASDAQ: WTER), a producer of premium bottled alkaline and flavored-infused drinking waters and CBD-infused products, today announced that it is now an approved vendor for Kampgrounds of America (“KOA”(R)) and Yogi Bear’s Jellystone Park(TM) Camp-Resorts. “We are pursuing some exciting growth opportunities in the hospitality segment and are thrilled to announce our newest partnership with two of North America’s leading family camping destination providers,” WTER president and CEO Ricky Wright said in the press release. “There are approximately 82 million camper households in the U.S., and the recent pandemic-related travel limitations are drawing more first-time campers to the activity. Camping and glamping booking services providers are reporting huge spikes in business, with some 400% busier than the same time last year. As such, our timing is perfect, and pursuing unique growth areas in the hospitality and foodservice arena remains a priority. As an approved vendor, our leading brands, Alkaline88 (R), and A88 Infused(TM) flavors, will be available to franchisors of approximately 520 KOA and 81 Jellystone Park Camp-Resort locations. In addition, KOA campgrounds will offer A88CBD(TM) products to adult guests. Our single-serve, eco-friendly and all-natural products are an ideal fit for this segment and will be offered at their retail camp stores and on-site foodservice operations. We believe our products’ availability at these high traffic locations represents a huge growth opportunity and will further enhance the brand equity of our lifestyle products.”

To view the full press release, visit https://ibn.fm/s60Rt

About The Alkaline Water Company

Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88 delivers perfect 8.8 pH-balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label: Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88 launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused flavored water is available in seven unique all-natural flavors with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused Products includes both the company’s lab-tested, full-spectrum hemp salves, balms, lotions, essential oils and bath salts, along with broad-spectrum hemp beverage shots, powder packs, oil tinctures, capsules and gummies. To learn more about the company, visit www.A88CBD.com and www.TheAlkalineWaterCo.com.

NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://ibn.fm/WTER

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in The Alkaline Water Company Inc. WTER | Leave a comment

Cybin Corp. Appoints New CEO with Impressive Health-Care Expertise

  • Cybin appoints health-care expert Doug Drysdale as new CEO.
  • Company confident that his extensive health-care sector background, international company management skills will strengthen Cybin partnerships.
  • New CEO says business model, talented management team positions company to examine new psychedelic-based therapies, delivery systems.

Cybin Corp.,a life sciences company advancing psychedelic pharmaceuticals, recently announced the appointment of Doug Drysdale as its CEO (https://ibn.fm/vOTXM). Drysdale brings more than three decades of experience in the health-care sector and will continue to grow its IP portfolio.

“With his myriad business accomplishments, Doug is the ideal leader for Cybin,” said Cybin co-founder and COO Paul Glavine. “We believe that his extensive health-care sector background and international company management skills will help Cybin strengthen partnerships, develop strategic alliances and expand our international presence. We believe his strong leadership experience will help focus Cybin during our initial path to profitability.”

Named an Ernst and Young Entrepreneur of the Year in 2012, Drysdale has served for 30 years in the health care sector. In 2014, he led the recapitalization of a NASDAQ-listed pharmaceutical company, raising $65 million as its corporate director. Following that move, Drysdale served as the company’s chairman and CEO. In that role, he focused on rebuilding the management team and board of directors; he also built a 220-person sales team. Under his continued leadership, the pharmaceutical company raised $465 million of capital; its enterprise value grew exponentially from $80 million to an estimated $800 million. 

Before that, Drysdale headed M&A efforts at Actavis Group, leading 15 corporate acquisitions across three continents. Those efforts included a high-profile public hostile takeover attempt in Central Eastern Europe. During that same period, Drysdale raised approximately $3 billion of capital and managed lending syndicates, including over 25 banks, to fund its growth. In 2012, Watson Pharmaceuticals bought Actavis for €4.25 billion.

Drysdale led Norwich Pharmaceuticals into a new period of prosperity, eventually becoming CEO of its parent company, Alvogen Group. During his time as CEO, he grew Norwich’s two-product offering to more than 25 products, strengthened the company’s R&D capabilities and improved staffing efficiency by 25%. 

“I am beyond excited to be joining the Cybin team,” said Drysdale. “I believe Cybin’s business model and talented management team uniquely positions the company to examine the efficacy of psychedelic-based therapies and delivery systems in treating mental illness and addiction disorders. I expect Cybin’s expanding development pipeline will allow the company to explore a cost-effective and timely array of health care alternatives. 

“We will continue to grow our IP portfolio organically and shall be looking to add to our IP through accretive acquisitions,” he continued. “Research to date is showing positive indications for the potential use of psychedelic-based therapies as alternatives to current chronic depression medications and habit-forming opioids, for various treatment-resistant issues such as eating disorders, smoking cessation, PTSD, anxiety and depression. Mental illness and addiction have profoundly personal meanings for me and affect millions of people worldwide. I am proud to be in a position at Cybin to work to try to help countless patients and their families through the development of novel treatments.”

Cybin is an innovator in the stagnant pharmaceutical sector, where it aims to become the first life science company to bring psilocybin medicine targeting major depressive disorder to market. 

For more information about this company, please visit www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to Cybin are available in the company’s newsroom at http://ibn.fm/Cybin

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Cybin Corp. | Leave a comment

MissionIRNewsBreaks – Net Element Inc. (NASDAQ: NETE), Mullen Technologies Ramping Up for EV Production

Net Element (NASDAQ: NETE) is transforming its business model to become a pure-play electric vehicle (“EV”) manufacturer through its merger with privately-held Mullen Technologies Inc. Mullen Technologies recently announced commencement of the build out of its pilot manufacturing facility and that it has begun taking pre-orders for its MX-05 fully electric SUV. Completion of the facility is expected by April 2021. Shortly thereafter, the company will begin assembly of certification prototypes with plans for the first consumer-ready MX-05 SUVs to roll off the production line by the second quarter of 2022. An article discussing this reads, “Mullen Technologies anticipates its remodeled manufacturing facility will produce up to 1,000 MX-05 EVs per year; the facility will also manufacture all other upcoming models, including the MX-07 and MX-03. The factory will be renovated to include general assembly and battery assembly capabilities; the structure will also house R&D and serve as a warehouse.”

To view the full article, visit https://ibn.fm/pFe89

About Net Element Inc.

Net Element operates a payments-as-a-service transactional and value-added services platform for small to medium enterprise (“SME”) in the United States and selected emerging markets. In the U.S., the company aims to grow transactional revenue by innovating SME productivity services using blockchain technology solutions and Aptito, its cloud-based, restaurant and retail point-of-sale solution. Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions. Net Element was ranked as one of the fastest-growing companies in North America on Deloitte’s 2017 Technology Fast 500(TM). In 2017 Net Element was recognized by “South Florida Business Journal” as one of 2016’s fastest-growing technology companies. Further information is available at www.NetElement.com.

NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE 

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Net Element Inc. NETE | Leave a comment

MissionIRNewsBreaks – Trxade Group Inc. (NASDAQ: MEDS) Shines Digital Spotlight on Telehealth Services, Smart Technology

Trxade Group NASDAQ: MEDS), an integrated drug-procurement, delivery and health-care platform, was showcased at several recent virtual conferences and events. In a realm not limited by location, the company’s leadership took advantage of the opportunity to boost exposure of Trxade’s innovative platform and solutions to potential investors. Among capabilities highlighted in the digital spotlight, Trxade’s business-to-consumer (“B2C”) services took center stage in relevance for today’s environment, where the most critical needs are met with a next-generation response. An article discussing this reads, “The company’s B2C operations are led via Bonum Health, which provides 24/7 access to Board-Certified Providers and Health Assessment Tools at a time when telehealth services are in high demand. Smart technology allows doctors and specialty providers to view vitals through special integrations like FitBit, iHealth, etc. Pending the outcomes of pilot programs, the company expects to make Bonum Health available nationwide.”

To view the full article, visit https://ibn.fm/ZMf51

About Trxade Group Inc.

Headquartered in Tampa, Florida, Trxade Group is an integrated drug-procurement, delivery and health-care platform that fosters price transparency, thereby improving profit margins for both buyers and sellers of pharmaceuticals. Trxade Group operates across all 50 states with the central mission of making health-care services affordable and accessible. Founded in 2010, Trxade Group is comprised of four synergistic operating platforms: (1) the Trxade B2B trading platform with 11,725 registered pharmacies; (2) Integra Pharma Solutions, Trxade Group’s virtual wholesale division; (3) the Bonum Health platform offering affordable telehealth services; and (4) the DelivMeds app, which coordinates a nationwide distribution network through independent pharmacies or mail-order delivery. For additional information, please visit www.Trxade.com, www.DelivMeds.com and www.BonumHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Trxade Group Inc. (MEDS) | Leave a comment

MissionIRNewsBreaks – Sigma Labs Inc. (NASDAQ: SGLB) Partners with Northwestern University to Develop DED Additive Processes

Sigma Labs (NASDAQ: SGLB), a leading developer of in-process, quality-assurance software for the commercial 3D-printing industry, has announced a new partnership with Northwestern University designed to develop its PrintRite3D(TM) In-Process Quality Assurance technology across an array of 3D printing processes. Sigma will work closely with its Northwestern University partner to expand the proprietary quality assurance technology and evaluate an application to powder-blow Directed Energy Deposition (“DED”) additive processes. Northwestern University acquired the first PrintRite3D DED system, and Sigma Labs developed the hardware and software for the system. The agreement calls for the installation of the beta system onto the customized open-architecture DED system, named Additive Rapid Prototyping Instrument (“ARPI”) system located at Northwestern’s Advanced Manufacturing Processes Laboratory (“AMPL”). Sigma Labs plans to seek additional commercial DED machine OEM partners to expand the beta testing program. DED has been applied in a variety of industries, including aerospace, oil and gas, defense, marine and architecture.” OEM’s have seen an increase in demand of the directed energy deposition machine ranging from high-level R&D projects to the production of prototype and production parts, many of which are for the aerospace industry,” said Sigma Labs CEO Mark Ruport in the press release. “This initiative expands our market opportunity and is the first step in Sigma’s strategy to apply our technology across a broad array of Additive Manufacturing processes.”

To view the full press release, visit https://ibn.fm/ngELP

About Sigma Labs Inc.

Sigma Labs is a leading provider of quality-assurance software to the commercial 3D-metal printing industry under the PrintRite3D(R) brand. Sigma specializes in the development and commercialization of real-time monitoring solutions known as PrintRite3D for 3D-metal advanced manufacturing technologies. PrintRite3D detects and classifies defects and anomalies in real time during the manufacturing process and informs the production manager of quality issues. Sigma Labs’ software product is a major catalyst for the acceleration and adoption of 3D metal printing. For more information, please visit www.SigmaLabsInc.com.

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, Sigma Labs Inc. SGLB | Leave a comment

MissionIRNewsBreaks – 180 Life Sciences Corp. Featured in NNW Editorial Discussing Big Pharma Acquisitions

180 Life Sciences Corp. was discussed prominently in an editorial published by NetworkNewsWire (“NNW”), one of 50-plus brands in the InvestorBrandNetwork (“IBN”). The editorial, titled “Banking on the Next Blockbuster Drug,” discusses the significant amounts of time and money being invested by big pharma companies in the pursuit of new drugs, especially those that offer the potential to become blockbuster drugs. A blockbuster drug, or one that generates more than $1 billion in annual sales, can provide enormous benefits for the company that owns and manufactures it. Therefore, large companies operating in the pharmaceutical space commonly acquire promising new drugs — and the companies that are developing those drugs. 180 Life Sciences is one of those companies. 180 Life Sciences Corpwas founded by four scientists that have a successful track record of developing new therapeutics that were acquired by larger pharmaceutical companies, sometimes for billions of dollars. The group of renowned scientist-entrepreneurs is focusing on replicating their past success with a pipeline of drug candidates in sequential stages of development that target untapped markets with significant potential.

To view the full press release, visit https://ibn.fm/kESoz

About 180 Life Sciences Corp.

180 Life Sciences is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. KBL Merger Corp. IV previously announced plans to merge with 180 Life Sciences and, in connection with the merger, consummated a bridge financing on June 29, 2020, and submitted its latest S4 filing with the SEC on Aug. 28, 2020. Close of the business combination is expected in the fourth quarter of 2020. Following the merger, the new company will be listed on the Nasdaq Capital Market under ticker symbol “ATNF.” For more information, visit the company’s website at www.180LifeSciences.com.

KBLM has valued 180 Life Sciences at $175 million, with the acquisition being carried out via a share swap, with each share of 180 Life Sciences to be exchanged for one share of KBLM.

NOTE TO INVESTORS: The latest news and updates relating to 180 Life Sciences are available in the company’s newsroom at http://ibn.fm/180

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in 180 Life Sciences Corp., KBL Merger Corp. IV KBLM, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Forms New Scientific Advisory Board

AzurRx BioPharma (NASDAQ: AZRX), a clinical-stage biopharmaceutical company focused on developing treatments for gastrointestinal diseases using recombinant proteins, has announced  the formation of a Scientific Advisory Board (“SAB”) designed to provide the company with invaluable expertise and insights. The company also announced that three leading global experts in exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis and chronic pancreatitis have been appointed to the board: Michael Konstan, MD; Darwin L. Conwell, MD; and Michael Wilschanski, MD. Konstanis vice dean for translational research and the Gertrude Lee Chandler Tucker Professor of Pediatrics at Case Western Reserve University School of Medicine; he is also the Austin Ricci chair in pediatric pulmonary care and research at University Hospitals Rainbow Babies and Children’s Hospital in Cleveland, Ohio. Konstan has spent his entire professional career in the care and research of people with cystic fibrosis (“CF”). Conwell is a gastroenterology physician-scientist specializing in pancreas disorders and is a professor of medicine at The Ohio State University College of Medicine where he serves as director of the Division of Gastroenterology, Hepatology and Nutrition at The Ohio State Wexner Medical Center. He is an NIH-funded physician-scientist with over 200 peer reviewed publications. The leader of numerous national and international studies of potentially new therapies in CF, Wilschanski is director of pediatric gastroenterology at Hadassah Hebrew University Medical Center. In addition, he also serves as the director of the Electrophysiology Laboratory in Hadassah where he performs in vivo and in vitro measurements of electrolyte transport, which is used diagnostically and therapeutically in CF. “We are thrilled to have this distinguished group of scientific leaders helping to guide our research and clinical development efforts as we advance our MS1819 program for the treatment of exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis patients,” said AzurRx CEO James Sapirstein in the press release.

To view the full press release, visit https://ibn.fm/4bTS5

About AzurRx BioPharma Inc.

AzurRx BioPharma is a biopharmaceutical company specializing in the research and development of nonsystemic biologics for gastrointestinal disorders. The company is focused on the development of its lead drug candidate, MS1819. AzurRx is currently conducting two Phase 2 clinical trials of MS1819: the OPTION 2 monotherapy trial, and the Combination therapy trial, consisting of MS1819 in conjunction with porcine-derived pancreatic enzyme replacement therapy, the current standard of care.  The company is headquartered in New York, NY, with scientific operations based in Langlade, France, and clinical operations in Hayward, California. For more information about the company, visit www.AzurRx.com.

NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at https://ibn.fm/AZRX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in AzurRx BioPharma Inc. AZRX, MissionIRNewsBreaks | Leave a comment

Predictive Oncology Inc. (NASDAQ: POAI) Industry Leader in Growing Precision Medicine Market

  • Recent study reports CAGR of 9.7% in precision medicine space.
  • Predictive Oncology focused on use of data, artificial intelligence to develop personalized cancer therapies.
  • One of POAI’s primary projects is building multi-omic predictive models of tumor drug response

A recent study of the global precision medicine market indicates a bright future for the industry, especially for U.S.-based companies focusing on cancer research, such as Predictive Oncology Inc. (NASDAQ: POAI). The study reported a CAGR of 9.7% in the sector, with North America dominating the market and oncology expected to hold the highest market.

“Precision medicine, a combination of molecular biology techniques and systems biology, is an emerging approach for disease treatment and prevention,” the Mordor Intelligence study stated. “The market growth for this approach is gaining momentum, as it takes into account individual variability in genes, environment and lifestyle for each person, while developing drugs and vaccines.”

The report goes on to note that North America currently dominates the precision medicine market and is “expected to continue its stronghold for a few more years.” The United States holds the largest market share on the continent, at least in part due to the Precision Medicine Initiative (“PMI”), launched by former President Barack Obama.

This initiative was designed to revolutionize medicine and generate the scientific evidence needed to move the concept of precision medicine into everyday clinical practice. The PMI enjoys widespread support, including ongoing efforts through the Department of Veteran’s Affairs (“VA”), the Food and Drug Administration (“FDA”), the Office of the National Coordinator for Health IT and the Office for Civil Rights.

The study also reports that “precision medicine applications are primarily directed toward better treatment against oncological diseases, with an estimated more than 30% market dominance over other segments. . . . The high support from the government through funding and rapid growth of genomic analysis are expected to augment the growth of the precision medicine market at a fast rate, over the forecast period.”

This analysis bodes well for Predictive Oncology, an industry leader focused on the use of data and artificial intelligence (“AI”) to develop predictive models of tumor drug response and outcome, which can be used to help oncologists individualize current cancer therapies for the patients as well as help researchers find new cancer therapies. The Mordor report noted that key factors propelling the growth of the precision medicine market include increasing online collaborative forums, increasing efforts to characterize genes and advancements in cancer biology — all of which POAI is involved in.

“The fundamental concept of precision medicine is to understand the genetic makeup and difference at a population level, and further at an individual level, in order to customize a drug that targets a particular gene type,” the report observed. “Hence, sequencing or characterizing genes is the most important method to gain information about genes and their possible mutations.”

One of POAI’s primary projects, conducted through its subsidiary Helomics, is building multi-omic predictive models of tumor drug response and outcome using a its unique proprietary TumorSpace knowledge base of 150,000 tumor drug response profiles gathered from over 15 years of clinical testing. Using artificial intelligence, the company is leveraging this data to build predictive models of tumor drug response. These models offer researchers in pharma, biopharma and diagnostic companies actionable information that drives the development of new precision therapies, companion diagnostics, biomarkers and helps design better-targeted trials — all with the end goal of helping patients diagnosed with cancer.

POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated, patient-derived (“PDx”) smart tumor profiling platform to provide oncologists with a road map to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.  

For more information about Predictive Oncology, please visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Completion of Manufacturing of Lead Drug Candidate

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, has completed the manufacturing process for Berubicin Drug Product. CNSP’s U.S. manufacturer, Pharmaceutics International Inc. (“Pii”), has finished manufacturing the drug, which is the company’s lead drug candidate for the treatment of glioblastoma multiforme (“GBM”), an aggressive form of incurable brain cancer. In an attempt to diversify its supply chain, provide for local accessibility of Berubicin and reduce COVID-19-related delay risks, CNS had implemented a dual-track drug product manufacturing approach that used two different manufacturers for the drug; the two companies are located in different countries. CNSP contracted with Pii to make the drug in the United States and is working with BSP Pharmaceuticals S.p.A. (“BSP”) in Italy as well. BSP is on schedule to complete manufacturing later this year. CNS has also partnered with three separate companies as it prepares for its upcoming clinical trial of Berubicin. Worldwide Clinical Trials is the project’s contract research organization, Image Analysis Group (“IAG”) is the imaging partner and Berry Consultants will be the biostatistical advisor for the Phase 2 trial design. “Completing the manufacturing process for Berubicin in the United States is an essential step in our preparations to file an IND during the fourth quarter of this year,” CNS Pharmaceuticals CEO John Climaco stated in the press release. “We are extremely pleased to achieve yet another milestone in our preparation efforts and demonstrate our continued ability to execute upon both our operational and clinical strategies in a timely and proficient manner. We remain committed to further progressing our trial preparations, as we look forward to initiating a U.S. Phase 2 trial for Berubicin during the first quarter of 2021.”

To view the full press release, visit https://ibn.fm/qfy7A

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. By the end of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the U.S., while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. The company’s second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. For more information about the company, visit www.CNSPharma.com

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in CNS Pharmaceuticals Inc. CNSP, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Why CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Is ‘One to Watch’

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system. A recent article discussing CNS Pharmaceuticals reads, “The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.”

To view the full article, visit https://ibn.fm/vYzGp

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006.  In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. By the end of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the United States, while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. The company’s second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies to be 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in CNS Pharmaceuticals Inc. CNSP | Leave a comment